CBD Research: Arthritis, Hepatic Impairment, Fragile X Syndrome

Scientists worldwide continue to study the effects of cannabinoids in general and CBD in particular. The science of how cannabinoids effect the brain and body is still in its infancy, due in part to governments having outlawed cannabis, making it difficult to impossible for institutions to conduct the research necessary to discover what appears to be a huge amount of potential to aid in health and wellness.

The fact that cannabis has been used safely for thousands of years across cultures is becoming common knowledge. As it becomes more apparent there is no reason cannabis should be banned, governments are lessening their control due to public pressure from those who are becoming increasingly aware of its benefits.

Cannabinoids and Arthritis

Source: https://www.ncbi.nlm.nih.gov/pubmed/30920973

The journal Current opinions in rheumatology published in its May 2019 edition an article with the excellent title, “Joints for joints: cannabinoids in the treatment of rheumatoid arthritis.” It seems obvious that since cannabinoids are known for their anti-inflammatory effects, that they would work well in the treatment of a disease that is caused by inflammation.

“In addition to controlling inflammation,” reads the abstract, “cannabinoids reduce pain by activating central and peripheral CB1, peripheral CB2 receptors and CBD-sensitive noncannabinoid receptor targets.”

Noting that further study is needed, as most journal articles about cannabinoids do, the article states “it is important to target the right receptors in the right place.”

CBD in Patients with Hepatic Impairment

Source: https://www.ncbi.nlm.nih.gov/pubmed/30921490

On March 28, Journal of Clinical Pharmacology published a study that tested CBD in patients with hepatic impairment (slowed liver functioning). A huge single dose (200 mg of “highly purified” CBD) was administered to the hepatic impairment patients as well as a control group with normal liver function.

The study found that exposure rates of total CBD and CBD metabolites were high in patients with moderate to severe hepatic impairment. While a lower starting dose was recommended in these patients, “CBD was well tolerated, and there were no serious adverse events reported during the trial.”

CBD and Symptoms Associated with Fragile X Syndrome

Source: https://www.ncbi.nlm.nih.gov/pubmed/30944868

According to the CDC, Fragile X Syndrome (FXS) is a genetic disorder “caused by changes in the fragile X mental retardation 1 (FMR1) gene. The FMR1 gene usually makes a protein called fragile X mental retardation protein (FMRP). FMRP is needed for normal brain development. People who have FXS do not make this protein.” Symptoms of FXS include “Social and behavior problems (such as not making eye contact, anxiety, trouble paying attention, hand flapping, acting and speaking without thinking, and being very active)”.

A literature review published March 13 in the relatively new journal Cannabis and cannabinoid research found “patients described in the case series exhibited functional benefit following the use of oral CBD+ solutions, including noticeable reductions in social avoidance and anxiety, as well as improvements in sleep, feeding, motor coordination, language skills, anxiety, and sensory processing”.

As usual in research about anything cannabis related, the authors stress the importance of studying this further: “Findings highlight the importance of exploring the therapeutic potential of CBD within the context of rigorous clinical trials.”

Leave a Reply

Your email address will not be published.